Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study to evaluate the effect of concomitant administration of GBT440 on
caffeine (a CYP1A2 probe substrate), S warfarin (a CYP2C9 probe substrate), omeprazole (a
CYP2C19 probe substrate), and midazolam (a CYP3A4 probe substrate) plasma concentrations.